Houte Hans Van Sells 2,845 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,845 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $23.38, for a total value of $66,516.10. Following the sale, the chief financial officer directly owned 44,927 shares in the company, valued at $1,050,393.26. This trade represents a 5.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, May 5th, Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.60, for a total value of $233,313.00.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $23.21 on Friday. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $25.08. The company has a market capitalization of $2.41 billion, a P/E ratio of -6.73 and a beta of 1.80. The business has a 50 day moving average price of $20.54 and a 200 day moving average price of $17.85.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The firm had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the topic of several recent research reports. HC Wainwright boosted their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Truist Financial raised their target price on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Mizuho lifted their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Oppenheimer initiated coverage on shares of Nurix Therapeutics in a report on Monday, June 29th. They issued an “outperform” rating and a $28.00 price target on the stock. Finally, UBS Group increased their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NRIX. Vanguard Group Inc. boosted its stake in shares of Nurix Therapeutics by 32.5% during the fourth quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after acquiring an additional 1,460,736 shares during the last quarter. General Atlantic L.P. purchased a new stake in Nurix Therapeutics during the 4th quarter worth about $92,899,000. Morgan Stanley raised its stake in Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after purchasing an additional 2,620,323 shares during the last quarter. Vestal Point Capital LP raised its stake in Nurix Therapeutics by 35.0% in the 4th quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company’s stock valued at $88,969,000 after purchasing an additional 1,215,000 shares during the last quarter. Finally, Baker BROS. Advisors LP lifted its holdings in Nurix Therapeutics by 20.0% in the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after purchasing an additional 776,431 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.